Livmoniplimab
Aliases
ABBV-151
4 clinical trials
4 abstracts
2 indications
Indication
Hepatocellular CarcinomaIndication
NSCLCAbstract
Targeting GARP–TGF-β1 with livmoniplimab plus anti–PD-1 budigalimab to remodel the immunosuppressive tumor microenvironment.Org: North Chicago,
Abstract
Phase 2/3 study of livmoniplimab in combination with budigalimab in patients with locally advanced or metastatic hepatocellular carcinoma.Org: Weill Medical College at Cornell University, Liver Oncology and Therapeutic Innovation Unit, AP-HP-Hôpital Beaujon, Clichy, France, Department of Oncology, National Taiwan University Cancer Center and National Taiwan University Hospital, Taipei, Taiwan, Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Department of Medicine, Section of Hematology and Oncology, University of Chicago,
Abstract
Phase 2 study of livmoniplimab in combination with budigalimab in patients with hepatocellular carcinoma.Org: Weill Medical College at Cornell University,
Abstract
Livmoniplimab with or without budigalimab in patients with advanced solid tumors: Results from the combination therapy in the urothelial carcinoma dose expansion cohort.Org: Hospital Clínico Universitario-INCLIVIA, Valencia, Spain, Universite Catholique De Louvain, Bruxelles, Belgium, Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, VA New York Harbor Healthcare System, Manhattan Campus, New York, NY, Yonsei University Health System and Songdang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, South Korea,
Clinical trial
A Randomized, Phase 2/3 Study to Evaluate the Optimal Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)Status: Recruiting, Estimated PCD: 2031-10-08
Clinical trial
A Phase 2/3, Randomized Study to Evaluate the Dose Optimization, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab in Subjects With Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Who Have Not Previously Received Systemic TreatmentStatus: Recruiting, Estimated PCD: 2030-09-06
Clinical trial
A Phase 2, Randomized Study to Evaluate the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Combination With Budigalimab for Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Patients Who Have Progressed After an Immune Checkpoint Inhibitor Containing Regimen in First-Line HCCStatus: Recruiting, Estimated PCD: 2026-12-23
Clinical trial
A Phase 1b Study to Evaluate the Safety and Pharmacokinetics of Livmoniplimab in Combination With Budigalimab in Chinese Subjects With Locally Advanced or Metastatic Child-Pugh A Hepatocellular Carcinoma Who Have Progressed After a First-Line Regimen That Includes an Immune Checkpoint InhibitorStatus: Not yet recruiting, Estimated PCD: 2027-10-27